New Blood Test for Alzheimer's Gets FDA Clearance—Here's How It Works
Summary
The FDA has approved a new blood test called PrecivityAD2 to help diagnose Alzheimer's disease in adults aged 40 and over who show symptoms of memory or thinking problems. This test detects amyloid proteins linked to Alzheimer's and is meant to be used alongside other medical exams, not by itself.Key Facts
- PrecivityAD2 is a blood test approved by the FDA for adults 40+ with signs of cognitive impairment.
- The test detects amyloid plaques, protein buildups in the brain tied to Alzheimer's disease.
- It is not a stand-alone screening tool but helps doctors confirm diagnosis with other evaluations.
- The test showed high accuracy: 97.6% positive predictive value and 93.1% negative predictive value in a study.
- Alzheimer's disease currently affects about 7.4 million Americans aged 65 and older, expected to rise to 13.8 million by 2060.
- Usual diagnosis includes symptom reviews, family interviews, lab tests, and brain scans.
- PrecivityAD2 may reduce the need for PET scans, which are more expensive and take longer.
- The test aims to simplify and speed up Alzheimer's diagnosis in clinical practice.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
